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ABSTRACT
Overexpression of HDAC1 Induces Functional β-cell Mass
Carrie Draney
Department of Nutrition Dietetics and Food Science, BYU
Master of Science
Type 2 diabetes is a metabolic disorder that results in β-cell dysfunction and ultimate
destruction, and leads to impaired glucose homeostasis. High rates of proliferation and
differentiation of pancreatic β-cells occurs mostly during neonatal development. However,
research shows these mechanisms remain intact as β-cell proliferation has been observed during
pregnancy and obesity. We have shown that overexpression of the β-cell transcription factor
Nkx6.1 is sufficient to induce β-cell proliferation. Exploration of the transcriptional targets of
Nkx6.1 has identified histone deacetylase 1 (HDAC1) as a down-stream target of Nkx6.1. Here
we demonstrate that HDAC1 overexpression is sufficient to induce β-cell proliferation, enhance
β-cell survival upon exposure to apoptotic stimuli and maintains glucose stimulated insulin
secretion (GSIS). Our data suggests overexpression of HDAC1 leads to p15/INK4b suppression,
a cell cycle inhibitor, potentially explaining the mechanism behind these observed effects. These
data demonstrate that HDAC1 overexpression is sufficient to induce β-cell proliferation and
enhance cell survival while maintaining glucose stimulated insulin secretion.
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Introduction
Type 1 (T1D) and Type 2 diabetes (T2D) affect more than 9% of the American
population and the incidences of diabetes continue to increase at a startling rate. Decreased β-cell
function is common with both T1D and T2D. Decreased function impedes insulin secretion and
causes unstable blood glucose levels. Recent studies demonstrate that β-cell proliferation occurs
most rapidly during embryogenesis and replication significantly decreases with age [1-3].
However, studies have shown that these mechanisms remain intact, as β-cell proliferation has
been observed during pregnancy and obesity[4-6]. Modifying this tightly regulated proliferative
mechanism could lead to potential treatments for diabetes.
We, and others, have shown that the homeobox β-cell transcription factor Nkx6.1 is
sufficient to induce β-cell proliferation [7, 8]. Developmental studies have shown that the rapid
period of embryonic β-cell replication is dependent on Nkx6.1 [9]. Furthermore, studies have
shown that Nkx6.1 inactivation causes rapid-onset diabetes, demonstrating the importance of
Nkx6.1 on β-cell proliferation and stability [10]. Our studies have shown that overexpression of
Nkx6.1 in primary rat and human β-cells results in a significant induction of β-cell proliferation.
Interestingly, while Nkx6.1 protein levels are observed as early as 24 hours after transduction
with AdCMV-Nkx6.1, there is a 72-hour delay in β-cell proliferation. This suggests that early
Nkx6.1 targets may be necessary to permit β-cells to reenter the cell cycle and proceed through
cellular replication.
HDAC1 is a member of the histone deacetylation enzyme family. HDAC1 plays an essential
role in the regulation of gene transcription, cell growth, and survival [11]. HDACs function by
removing acetyl groups from histones, which results in decreased gene expression. HDACs have
been shown to downregulate expression of cell cycle inhibitors through post translational
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modifications. Recent studies suggest that HDAC1 plays an important role in cell cycle
regulatory pathways, making HDACs an ideal target for inducing β-cell proliferation [12].
HDACs have also been shown to have anti-inflammatory activity and play a role in insulin
signaling, thus potentially allowing the HDACs to enhance cell survival while maintaining
insulin secretion [13-15].
HDACs have been shown to modulate specific cell cycle regulators. Researchers show
inhibition of HDAC specifically upregulates the cell cycle regulator p15/INK4b leading to
decreased cell growth [16]. Consistently, our data suggests over expression of HDAC1 leads to
suppression of p15/INK4b. P15/INK4b is a specific inhibitor of the cyclin D-dependent kinases
and impacts cells in the G1 phase of the cell cycle. We predict overexpression of HDAC1 leads
to β-cell proliferation through p15/INK4b suppression.
In this study we demonstrate that HDAC1 is induced by transcription factor Nkx6.1. We
show that HDAC1 is sufficient to induce β-cell proliferation, and is necessary for Nkx6.1
mediated proliferation. We demonstrate that HDAC1 overexpression in β-cells maintains glucose
stimulated insulin secretion (GSIS) and increases β-cell survival when exposed to apoptotic
stimuli. Furthermore, we demonstrate that overexpression of HDAC1 results in increased
expression of cell cycle regulators and down-regulation of the cell cycle inhibitor p15/INK4b.
Our data demonstrate that HDAC1 is necessary for Nkx6.1 mediated β-cell proliferation, and
suggests that HDAC1 activation could be used to increase β-cell mass ex vivo for transplantation
or in vivo to increase a patient’s residual β-cell mass.
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Methods
Cell Culture
832/13 rat insulinoma β-cells were cultured as previously described [17]. For chemical
inhibition of HDAC1, cells were cultured with 200 nM trichostatin A (TSA) in DMSO for 24
hours.
Adenoviral Cloning and Preparation
Recombinant HDAC1 adenovirus was generated and purified as previously described
[18]. HDAC1 overexpression was verified using RT-PCR. Adenoviruses expressing Nkx6.1 and
GFP have been described elsewhere [7, 19].
Islet Isolation and Culture
Islet isolation from Wistar rats (Harlan, Indianapolis, IN, USA) was completed as
described [17]. All animal studies were approved and performed in accordance with Brigham
Young University’s IACUC guidelines. Islet isolation, culture, and transduction were completed
as described [17, 20, 21].
[3H]-Thymidine Incorporation
DNA synthesis rates were measured by [methyl-3 H]-thymidine incorporation and were
completed as described [17, 20, 21].
Cell Viability Assays
The 832/13 cells were transduced with AdCMV-GFP, AdCMV-HDAC1, or left untreated
(No Virus-NV). After transduction, cells were treated with apoptotic stimulants (9.14uM
etoposide, 0.31uM thapsigargin, and 2.01uM camptothecin) and viability was determined as
described [22].
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EdU Incorporation
Islet EdU (Invitrogen, Waltham, MA, USA) incorporation, with DAPI and insulin
(DAKO, Carpinteria, CA, USA) counterstaining, was completed as described [21]. Three
sections containing ≥400 nuclei were evaluated for EdU signals using IMAGEJ software
(National Institutes of Health, Bethesda, MD, USA) for each condition.
Glucose-Stimulated Insulin Secretion
Glucose-stimulated insulin secretion assays from rat islets or 832/13 cells were
completed as described [20, 23]. Secreted insulin and total insulin were measured using a rat
insulin RIA kit (MP Biomedicals, Santa Ana, CA, USA) [17].
RT-PCR
RNA isolation, cDNA synthesis, and RT-PCR were performed as described [17, 22]
using Taq-man assays on demand probes and primers for GFP, Nkx6.1, HDAC1, Cdet1, Cdc2a,
Cdc6, Cdk2, Cyclin A2, Cyclin B1, Cyclin D2, Cyclin E1, E2F1, FoxM1, AURKA, HDAC7,
Nr4a1, Nr4a3, p15, p21, p27, p57, p16, p15, p18, p19 and PPIA (Life Technologies). Primer
sequences are available upon request.
Statistical Analysis
Data was analyzed using two-tailed Student t test or two-way ANOVA where appropriate
(Prism Software). Statistical significance was defined as P< 0.05.
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Results
Nkx6.1 Induces HDAC1 Expression and is Necessary for Proliferation
We have shown that AdCMV-Nkx6.1 transduced primary rat and human β-cells
proliferate after 72 hours [7] suggesting down-stream targets are needed for Nkx6.1 mediated
proliferation. Analysis of previously published microarray data demonstrate that HDAC1 is
induced within 48 hours of Nkx6.1 overexpression [21]. We measured HDAC1 mRNA levels in
primary rat islets transduced with AdCMV-Nkx6.1 at 24, 48, 72 and 96 hours after transduction.
Islets transduced with AdCMV-Nkx6.1 were compared to AdCMV-GFP transduced and
untreated islets. HDAC1 mRNA levels were significantly increased 48 hours after Nkx6.1
overexpression, and remained elevated throughout the 96 hour time course (Fig 1A).

Figure 1. HDAC1 is induced by Nkx6.1 in β-cells, and HDAC activity is necessary for
Nkx6.1 mediated proliferation.
(A) Rat islets were transduced with AdCMV-Nkx6.1, AdCMV-GFP or left untreated and
HDAC1 mRNA levels were measured at 24, 48, 72 and 96 hours after transduction using RTPCR. (B) Cells were transduced with AdCMV-Nkx6.1, Ad-CMV-GFP or left untreated and
exposed to 200 nmol/ml TSA in order to chemically inhibit HDAC. Islet proliferation was
measured by [3H]-thymidine incorporation. For each experiment n=3-5 replicates per
condition. ***p<0.001.
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Furthermore, to determine if HDAC1 is necessary for Nkx6.1 mediated proliferation, primary rat
islets were transduced with AdCMV-Nkx6.1 and compared to AdCMV-GFP or untreated islets
and cultured for 96 hours. At 72-hours of culture the cells were treated with either HDAC
inhibitor TSA or vehicle control (DMSO) and labeled with 3H-thymidine. While Nkx6.1 is able
to induce β-cells proliferation when cultured with DMSO, addition of TSA significantly inhibits
Nkx6.1 mediated β-cell proliferation (Fig 1B). These data demonstrate that Nkx6.1 induces
expression of HDAC1 and that HDAC1 activity is necessary for Nkx6.1 mediated proliferation.
Overexpression of HDAC1 Induces β-cells Proliferation
To determine if HDAC1 is sufficient to induce β-cell proliferation, 832/13 cells were
transduced with AdCMV-GFP or AdCMV-HDAC1 and compared to untreated cells. HDAC1
overexpression increased 832/13 cellular proliferation as compared to untreated cells or cells
expressing GFP (Fig 2A). In addition, we validated our results by transducing primary rat islets
with AdCMV-GFP or AdCMV-HDAC1 and comparing to untreated islets. The primary islets
were labeled with 3H-thymidine and incorporation was measured at 24, 48, 72 and 96 hours to
determine if HDAC1 induced proliferation of primary islets. Supporting our studies in the
832/13 β-cells, HDAC1 overexpression resulted in a significant increase in islet proliferation as
compared to untreated islets or islets expressing GFP (Fig 2B).
To determine if HDAC1 is necessary for basal 832/13 β-cell proliferation, we transfected
β-cells with siRNA against HDAC1, HDAC2, HDAC7, or HDAC10. 3H-thymidine labeling was
used to determine proliferation 96 hours after knockdown. Comparing untransfected and cells
transfected with a scrambled control (siCTRL) demonstrated that siRNA mediated HDAC1
knockdown resulted in decreased 3H-thymidine while knockdown of the other HDACs had no
significant effect on cellular proliferation (Fig 2C).
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Our data demonstrate that HDAC1 is sufficient and necessary for proliferation in primary
rat islets. To determine if β-cells specifically replicate in response to HDAC1 overexpression,
primary rat islets left untreated or transduced with AdCMV-GFP or AdCMV-HDAC1 were
cultured with the thymidine analog Edu for 96 hours. Islets were dispersed and the percentage of
insulin positive and Edu positive and insulin negative and EdU positive cells were
calculated. Our findings demonstrate that untransduced islets and islets transduced with
AdCMV-GRP had less than 1% of cells positive for EdU in the insulin positive and insulin

Figure 2. HDAC1 overexpression induces β-cell proliferation.
(A) 832/13 cells were transduced with AdCMV-GFP, AdCMV-HDAC1 or left untreated. Cell
proliferation was determined 96 hours after transduction by cell counts. (B) Rat islets were
transduced with AdCMV-GFP, AdCMV-HDAC1 or left untreated and 3H-thymidine
incorporation was measured at 24, 48, 72 and 96 hours to determine proliferation. (C) 832/13
cells were transfected with siRNA against HDAC1, HDAC2, HDAC7, HDAC10. 3Hthymidine labeling was used to determine proliferation 96 hours after knockdown. For each
experiment n=3-5 replicates per condition. (D) Rat islets were transduced with AdCMV-GFP,
AdCMV-HDAC1 or left untreated and cultured with the thymidine analog EdU for 96 hours.
Islets were dispersed and the percentage of Insulin+Edu+ and Insulin−EdU+ cells were
calculated. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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negative population (Fig 2D). Comparatively, islets transduced with AdCMV-HDAC1 had
significantly greater amounts of insulin positive Edu positive cells (Fig 2D). These data
demonstrate that overexpression of HDAC1 induces β-cell specific proliferation.
HDAC1 Overexpression Maintains Glucose Stimulated Insulin Secretion
Our previous data demonstrated that Nkx6.1 overexpression, in addition to inducing βcell proliferation, enhanced glucose stimulated insulin secretion (GSIS). Therefore, we sought to
determine the effect of HDAC1 overexpression on GSIS. 832/13 β-cells were transduced with
AdCMV-GFP, AdCMV-HDAC or cells were left untreated. Insulin secretion was measured 96
hours after transduction. No significant changes in insulin content were observed in any of our
experimental conditions (Fig 3A). Furthermore, no differences were observed in insulin secretion
at a non-stimulatory (2.5 mM glucose) or stimulatory (16.7mM glucose) environment (Fig 3B).

Figure 3. Overexpression of HDAC1 maintains glucose stimulated insulin secretion.
(A) Rat islets were transduction with AdCMV-GFP, AdCMV-HDAC1 or left untreated, and
glucose stimulated insulin secretion was measured 96 hours later by insulin RIA. (B) Total
insulin content was measured in 832/13 cells 96 hours after transduction with AdCMV-GFP,
AdCMV-HDAC1 or left untreated. For each experiment n=3 replicates per condition.
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These data demonstrate that HDAC1 overexpression, which results in enhanced β-cell
proliferation, maintains insulin secretion and produces functional β-cells.
HDAC1 Overexpression Protects Against Apoptotic Stimuli
To determine the effects of HDAC1 overexpression on cell survival, 832/13 cells were
treated with AdCMV-GFP, AdCMV-HDAC1 or left untreated. Twenty-four hours after
adenoviral transduction, cells were cultured with apoptotic stimuli for 18 hours using
camptothecin, thapsigargin, etoposide, or the vehicle control. Untransduced cells or cells
transduced with AdCMV-GFP demonstrated between 40% and 50% viability after cultured with
the respective apoptotic stimuli. Interestingly, cells overexpressing HDAC1 demonstrated a
significant increase in cell viability when treated with etoposide or thapsigargin (Fig 4 A,B) but
not with camptothecin (Fig 4A). These data demonstrate that HDAC1 overexpression protects
832/13 β-cells from etoposide or thapsigargin induced apoptosis.

Figure 4. HDAC1 overexpression protects β-cells from drug induced apoptosis.
832/13 cells were transduced with AdCMV-GFP, AdCMV-HDAC1 or left untreated. Twentyfour hours after adenoviral transduction, cells were cultured for 18 hours in the presence of
(A) camptothecin, (B) thapsigargin, (C) or etoposide. Cell counts were completed 18 hours
after drug treatment and cell viability was determined by comparing the untreated population
to the treated population. For each experiment n=3-5 per condition. *p<0.05.
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HDAC1 Overexpression Induces Changes in Cell Cycle Gene Expression
To determine if HDAC1 modifies specific cell cycle genes, primary rat islets were
transduced with AdCMV-GFP, AdCMV-HDAC1 or left untreated. Islets were harvested 96
hours after adenoviral transduction, and mRNA expression of cell cycle genes were measured
using RT-PCR. RT-PCR were performed as described [17, 22] using Taq-man assays on demand
probes and primers for GFP, Nkx6.1, HDAC1, Cdet1, Cdc2a, Cdc6, Cdk2, Cyclin A2, Cyclin
B1, Cyclin D2, Cyclin E1, E2F1, FoxM1, AURKA, HDAC7, Nr4a1, Nr4a3 and PPIA (Life
Technologies). These data demonstrate HDAC1 overexpression promotes S to G2 cell cycle
progression (Fig 5A).
Furthermore, to determine the specific mechanism by which HDAC1 upregulates cell
cycle genes, primary rat islets were transduced with AdCMV-GFP, AdCMV-HDAC1 or left
untreated. Islets were harvested after 96 hours and mRNA expression of cell cycle regulators

Figure 5. HDAC1 overexpression induces changes in cell cycle gene expression.
Primary rat islets were transduced with AdCMV-GFP or AdCMV-HDAC1. Cells were
harvested 96 hours after transduction and mRNA expression for (A) a panel of cell cycle
activators and (B) cell cycle inhibitors was measured using RT-PCR. For each experiment
n=3-5 per condition. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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were measured using RT-PCR. RT-PCR were performed as described [17, 22] using Taq-man
assays on demand probes and primers for p15, p21, p27, p57, p16, p15, p18, p19 and PPIA (Life
Technologies). Islets overexpressing HDAC1 showed a significant increase in p57 but more
importantly a decrease in p15/INK4b expression, a known cell cycle inhibitor (Fig 5B).
Together, these data suggest that HDAC1 overexpression may result in suppression of
p15/INK4b expression, thus allowing greater S to G2 cell cycle progression.
P15/INK4b Expression is Suppressed with HDAC1 Overexpression
Finally, to verify the previous p15/INK4b suppression, siCTRL and sip15/INK4b treated
832/13 β-cells were transduced with AdCMV-GFP, AdCMV-HDAC1 or left untreated. As
previously shown, HDAC1 overexpression leads to greater proliferation when compared to
untreated cells or cells expressing GFP. Moreover, cells deficient for p15/INK4b had enhanced
proliferation, and cells deficient for p15/INK4b that overexpressed HDAC1 had the greatest

Figure 6. p15/INK4b knockdown enhances HDAC1 mediated β-cells proliferation.
(A) siCTRL and sip15/INK4b treated 832/13 cells were transduced with AdCMV-GFP,
AdCMV-HDAC1 or left untreated. Cell counts were completed 96 hours after transduction to
determine cell viability. For each experiment n=3-5 per condition. **p<0.01, ****p<0.0001.
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level of proliferation (Fig 6A). These data demonstrate that p15/INK4b inhibits β-cell
proliferation, and that the loss of p15/INK4b results in improved HDAC1 mediated proliferation
(presumably through stimulation of the cell cycle activators previously demonstrated).
Discussion
All forms of diabetes ultimately result in β-cell destruction. While most β-cell
proliferation is limited to embryogenesis and the neonatal period [1], the process can be activated
during circumstances such as pregnancy and obesity, demonstrating that the process is
fundamentally intact [4, 5]. Thus, with proper stimulation, this tightly regulated process could be
activated to increase functional β-cell mass as a treatment modality for diabetic individuals
through ex vivo expansion of β-cells as sources for islet transplantation or in vivo expansion of
endogenous β-cells.
The β-cell transcription factor Nkx6.1 is sufficient to induce β-cell proliferation [7, 21].
Nkx6.1 mediated proliferation is observed 72 hours after overexpression in primary β-cells,
suggesting early Nkx6.1 targets may be necessary to permit β-cells to reenter the cell cycle and
proceed through cellular replication. Previously published microarray data demonstrate that
HDAC1 is induced within 48 hours of Nkx6.1 overexpression [21]. In this study, we show that
HDAC1 is induced through Nkx6.1 overexpression in β-cells. We demonstrate that HDAC1
activity is necessary for Nkx6.1 mediated β-cell proliferation, and that HDAC1 knockdown
significantly decreases β-cell proliferation. Our data demonstrates that HDAC1 overexpression
in primary rat β-cells or the INS-1 832/13 β-cell line is sufficient to induce proliferation, while
maintaining insulin secretion and insulin content. We demonstrate that HDAC1 overexpression
is sufficient to protect INS-1 832/13 β-cells from etoposide and thapsigargin induced cell death.
Concomitant with the observed β-cell proliferation, we demonstrate that HDAC1 overexpression
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enhances expression of key cell cycle genes, as well as decreases expression of the cell cycle
inhibitor p15/INK4b. Finally, we demonstrate that p15/INK4b knockdown in the INS-1 832/13
β-cell line is sufficient to enhance HDAC1 mediated proliferation. Together, our data
demonstrates that HDAC1 is able to induce β-cell proliferation by decreasing expression of the
cell cycle inhibitor p15/INK4b.
Interestingly, all HDACs (1-11) are expressed in INS-1 cells and rat islets, suggesting
their conceivable function in β-cell growth [24]. Studies propose HDACs play a vital role in
development of pancreatic endocrine tissue. Specifically, one study demonstrates HDAC1
expression is observed in pancreatic tissue during development and expression decreases with
aging [25]. These results mimic β-cell proliferation with increased rates during neonatal
development and β-cell proliferation absent during maturity. Other studies showed that deletion
of HDAC enzymes had deleterious effects on animals and completely blocked early embryonic
β-cell development, demonstrating the importance of HDAC’s in β-cell development [26-28]. In
mature β-cells, deletion of specific HDACs in mice and cell models decreases pancreatic insulin
content and increased susceptibility to developing type 2 diabetes [29]. Our data is supported by
these findings and demonstrate a correlation between HDAC1 expression and β-cell
proliferation. Taken together, these data describe a critical role for HDAC1 in β-cell
development.
The results demonstrating HDAC1 overexpression provided apoptotic protection are
somewhat controversial. A recent study indicated that HDAC1 knock down significantly
protected INS-1 cells from cytokine induced apoptosis [30], and other studies demonstrated that
HDAC inhibition can prevent inflammation and reduce apoptosis [30-33]. While these studies
have focused on the use of HDAC inhibitors, we have not found any studies which focus on the
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protective effects of HDAC1 overexpression. In addition, in comparing our findings and these
previously published findings there are differences in the type of apoptotic stimuli, cell lines, and
methods of HDAC inhibition. Our data is supported by other reports that demonstrate in β-cells
that other HDACs act as pro-apoptotic but concluded HDAC1 concomitantly did not add to the
apoptotic phenotype and may in fact be counterproductive [34]. In addition, other reports looking
at HDAC3 and HDAC1 inhibition in islets showed similar results and concluded knockdown of
HDAC1 did not provide apoptotic protection [35, 36]. Taken together, these data do support a
role for HDAC1 in providing apoptotic protection; however, at the moment it is unclear how
HDAC1 activity stimulates this protection in varying cell lines.
Class I HDACs primarily function in the nucleus and are responsible for removing acetyl
groups from histone lysine residues [27]. Histones are responsible for packaging the DNA into
chromatin complexes [37] and posttranslational modification of these chromatin complexes
regulates gene transcription and other cellular functions. HDACs removal of acetyl groups
generally results in a more compact chromatin structure resulting in decreased gene expression
[38]. Our findings and others demonstrate that HDAC1 directly regulates cell cycle genes and
modifies p15/INK4b expression [16]. p15/INK4b is a known cell cycle inhibitor and studies
show upregulation leads to cell cycle arrest [39, 40]. With HDAC1 overexpression we also see
an induction of p57/KIP2. However, these results have been observed with various β-cell
proliferative genes, and should only counteract proliferative actions [21, 41]. Our findings of
HDAC1 cell cycle modifications are supported by other findings that demonstrate a correlation
between HDAC1 and suppression of cell cycle inhibitors [42, 43]. Taken together, these data
describe a potential pathway by which HDAC1 overexpression mediates β-cell proliferation.
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Conclusion
In summary, we have demonstrated that HDAC1 acts as a down-stream Nkx6.1 target
that is necessary and sufficient for β-cell proliferation. The increased proliferation occurs with
maintenance of GSIS and increased protection from apoptotic stimuli. Our data demonstrate that
HDAC1 overexpression results in enhanced expression of cell cycle genes and decreased
expression of the cell cycle inhibitor p15/INK4b. Our data suggests that induction of
proliferation is an effect of enhanced HDAC activity resulting in decreased p15/INK4b
expression, presumably through decreased acetylation of the p15/INK4b. These findings and
others directly link decreased cell cycle regulators to increased functional β-cell mass [17, 21,
22]. These results suggest that inhibition of the cell cycle inhibitor, specifically here p15/INK4b,
may be a critical step for increasing β-cell proliferation as a treatment modality for individuals
with diabetes.
Future Direction
Our goal is to determine the mechanism by which HDAC1 and p15/INK4b interact in
order to induce β-cell proliferation. We will use chromatin immunoprecipitation as previously
described [7, 17, 21] to quantify the amount of acetylation at the p15/INK4b promoter site. With
overexpression of HDAC1, we expect to measure decreased acetylation at the promoter site.
With chemical inhibition of HDAC1 through TSA, we expect the opposite effect of increased
acetylation to be observed. We also hypothesize that overexpression of HDAC1 will result in an
increase of HDAC1 at this site, as well as a reduced effect when TSA is present. Together, these
experiments will help us understand if a direct binding relationship exists between HDAC1 and
the p15/INK4b promoter.
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APPENDIX A
Problem Statement
Decreased β-cell function is a common characteristic with Type 1 and Type 2 diabetes.
Decreased β-cell function impedes insulin secretion and causes unstable glucose levels in the
body. Increasing β-cell mass and function could be used as a treatment for diabetes. β-cell
proliferation occurs most rapidly during embryogenesis and replication decreases immensely
with age [1-3]. However, studies have shown that these mechanisms remain intact, as β-cell
proliferation has been observed during pregnancy and obesity [4-6]. Modifying this tightly
regulated proliferative mechanism could lead to potential treatments for diabetes.
During these unique periods of mature β-cell replication, expression of the β-cell
transcription factor Nkx6.1 increases and is necessary for the development of insulin-producing
β-cells [7, 8]. Furthermore, Nkx6.1 inactivation causes rapid-onset diabetes, demonstrating the
importance of Nkx6.1 on β-cell proliferation and stability [10]. Our studies have shown that
overexpression of Nkx6.1 in primary rat and human β-cells results in a significant induction of βcell proliferation after 72-hours of viral transduction. This delay suggests that early Nkx6.1
targets may be necessary to permit β-cells to reenter the cell cycle and proceed through cellular
replication.
We identified HDAC1 as a gene upregulated as early as 48 hours after introduction of
Nkx6.1 expression. HDAC1 is a member of the histone deacetylation enzyme family and plays
an essential role in the regulation of gene transcription, cell growth, and cell survival [11].
Recent studies suggest that HDAC1 plays an important role in cell cycle regulatory pathways,
making HDACs an ideal target for inducing β-cell proliferation [12].
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Increasing proliferation and function of β-cells through HDAC1 overexpression could
potentially be used as a cure for diabetes by increasing β-cell mass for ex vivo transplantation or
in vivo proliferation of residual β-cells. With the incidences of diabetes increasing at a starting
rate, a treatment for diabetes is an essential need for the diabetic community.
Purpose
The purpose of this research is to determine the following:
1. Does overexpression of HDAC1 induce β-cell proliferation in INS1 832/13 cells and
primary rat islets?
2. Can overexpression of HDAC1 enhance glucose stimulated insulin secretion (GSIS)?
3. Does overexpression of HDAC1 exhibit protective properties and increases β-cell
survival when exposed to apoptotic stimuli?

20

APPENDIX B
Literature Review
Type 1 and Type 2 diabetes are a disease of improper glucose homeostasis due to β-cell
dysfunction and loss. According to the American Diabetes Association, an estimated 29.1
million Americans suffer from diabetes and on average 1.4 million Americans are diagnosed
each year. As diabetes incidences continue to increase at a startling rate, treatment options and
potentially a cure are essential for these inflicted individuals. Currently, minimal research is
available regarding the β-cell proliferation pathway during embryogenesis and even less is
known about inducing ex vivo mature β-cell proliferation. However, from multiple study it is
known β-cell proliferation predominately occurs during adolescence and little proliferation
occurs after the first three years of life [1-3]. Nevertheless, studies show that the proliferation
pathway involved in β-cell propagation remains intact throughout maturity [4-6]. Understanding
the mechanism behind β-cell proliferation is an important step to modifying the pathway to
increase β-cell mass in diabetic patients, potentiating a cure for the disease.
A specific homeobox transcription factor known in the β-cell pathway is Nkx6.1. This
specific homeobox transcription factor is upregulated during the β-cell proliferation pathway and
expression of this specific gene is necessary for β-cell growth [7, 8]. Our research showed a
down-stream target induced during Nkx6.1 mediated β-cell proliferation was the enzyme histone
deacetylase 1 (HDAC1). HDAC1 is involved in posttranslational modification of DNA and is
responsible for monitoring the activity of histone acetyltransferases. Studies showed that deletion
of HDAC1 and HDAC2 completely blocked early β-cell development eluding to HDAC1’s
function in β-cell expansion [26]. Therefore, suggesting HDAC1 overexpression may upregulate
the β-cell proliferation pathway. Our preliminary data and the literature suggests HDAC1 plays
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an essential role in the β-cell proliferation pathway and overexpression could activate this highly
regulated pathway to increase functional β-cell mass.
HDAC enzymes have been classified into four groups based on function and DNA
sequence similarities [38]. HDAC1 is a member of the class I HDAC family and plays a specific
role in cell proliferation and regulation. Class I HDACs are primarily expressed in the nucleus
and are responsible for removing acetyl groups from lysine residues predominantly on histones
[27]. Histones are proteins found in the nucleus of each cell and are responsible for packaging
the DNA into chromatin complexes [37]. Posttranslational modification of these chromatin
complexes regulates gene transcription and other cellular functions. Two enzymes involved in
post-translational modifications are histone acetyl transferase [34] and HDAC [38]. HAT is an
enzyme responsible for transferring acetyl groups to the histones while HDACs balance this act
by removing these acetyl groups. HATs generally increase gene expression while HDACs
generally result in a more compact chromatin structure resulting in decreased gene expression.
HDACs critical role in chromatin remodeling makes this class of enzymes important regulators
of gene transcription, cell proliferation, and apoptosis.
Studies report HDAC1 as an essential modulator for cell survival and proliferation [44].
To determine the need for HDAC1 in cell proliferation, studies disrupted HDAC1 and observed
deleterious effects on animals. Knockdown of HDAC1 led to embryo lethality and decreased
embryonic stem cell proliferation [27, 28]. In addition to these findings, deletion of HDAC1 in
mouse embryonic fibroblast cells showed slowed proliferation and increased apoptosis [28].
Other studies showed that during times of increased proliferation, HDAC1 expression was
increased and was necessary for normal cell cycle progression [45]. Each of these studies verifies
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HDAC1’s essential role in cell survival and proliferation and suggests HDAC1 could be a viable
target to induce functional β-cell proliferation.
HDAC1 also play an essential role in the inflammatory pathway; however, it’s beneficial
effects are controversial. Diabetes is categorized as an inflammation related disease and therefore
reducing levels of inflammation could lead to greater β-cell proliferation and survival. Studies
report HDACs as regulators of the inflammatory pathway by controlling macrophage and
dendritic cell function. HDAC1 has direct connections to the inflammation signaling pathway
and acts as a controller for interferon and hypoxia-inducible factor-1 alpha inflammatory
responses [26]. A direct link between HDAC1 and inflammatory cytokine production has been
observed and again emphasized the important regulatory role of HDAC1 in the inflammatory
pathway [46]. Few studies explore the effects of HDAC overexpression and in fact, many studies
see positive effects of HDAC inhibitors on inflammatory diseases. Contrary to what we desire, in
many inflammatory related diseases HDAC inhibition can rescue cells from inflammation and
reduce apoptosis [30-33]. However, these discrepancies many be related to diverse cell lines,
varying HDAC inhibition and differing apoptotic stimuli. Nonetheless, subsequent studies have
reported in β-cells other HDACs as pro-apoptotic but concluded HDAC1 concomitantly does not
add to the apoptotic phenotype and may in fact be counterproductive [34]. Taken together, these
studies suggest a direct link between HDAC1 and the inflammatory pathway which could lead to
increased β-cell survival rates and provide apoptotic protection.
HDAC1 has the ability to directly modulate the cell cycle by regulating specific cell cycle
genes making it an ideal target for β-cell proliferation. It has been observed that deletion of
HDAC1 and HDAC2 leads to upregulation of p21 and p57 which are regulators of the G1 phase
in the cell cycle [47]. Upregulation of these cell cycle regulators decreases cell cycle progression
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by blocking cyclin-CDK complexes and inhibits cell growth. Other studies show a direct
correspondence between HDAC1 and suppression of cell cycle inhibitors [42, 43], therefore
suggests a possible mechanism by which HDAC may potentiate a way for mature β-cells to
proliferate. This regulator quality of HDAC1 makes it an ideal target for enhancing β-cell
proliferation.
In conclusions, many studies have revealed the correlation between HDAC1 and cell
proliferation. We have seen HDAC1 plays a key role in the development of β-cells and could act
as potential target for mature β-cell propagation. It is also inevitable that HDAC1 plays an
essential role in the inflammatory pathway and that overexpression of HDAC1 may have a
protective effect on β-cell apoptosis. HDAC1 also has the ability to directly regulate the cell
cycle and can therefore modulate this pathway to allow for greater cell cycle progression.
Together, these properties suggest HDAC1 could be a potential target for β-cell proliferation and
could provide protection against apoptotic stimuli, therefore increasing functional β-cell mass.
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APPENDIX C
Presentations
EXPERIMENTAL BIOLOGY 2016
Overexpression of HDAC1 induces functional β-cell mass.
Carrie Draney, Amanda Hobson, Jeffery Tessem
β-cell mass is lost in both major forms of diabetes. Mature β-cells have restricted proliferative
capacity. Studies aimed at increasing β-cell mass frequently have the unwanted side effects of
decreased glucose stimulated insulin secretion (GSIS) or increased apoptotic rates. Understanding
the molecular pathways that enhance β-cell mass while maintaining or improving GSIS and the
response to apoptotic stimuli could be used as a potential treatment for diabetes. Overexpression
of the β-cell transcription factor Nkx6.1 induces β-cell proliferation, enhances GSIS and protects
against apoptosis. Here we present data demonstrating that HDAC1 is induced by Nkx6.1, in
sufficient to induce β-cell proliferation, and is necessary for Nkx6.1 mediated proliferation.
HDAC1 overexpression maintains GSIS and increases β-cell survival when exposed to apoptotic
stimuli. Overexpression of HDAC1 results in increased expression of cell cycle controlling genes
and down-regulation of the cell cycle inhibitor p15/INK4b. We present a model by which HDAC1
is necessary for Nkx6.1 mediated β-cell proliferation by down-regulating p15/INK4b expression.
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